S&P 500 (INDEXSP: .INX) correction could continue
UK, France Suffer Record Jump In COVID-19 Cases As New York Hospitals Report Alarming Spike: Live Updates
Some severe COVID-19 cases linked to genetic mutations or antibodies that attack the body
White House Could Attempt to Overrule Potential New FDA Vaccine Guidance
The first rule of BookClub? No boring book clubs.
Antibodies protect against wide range of influenza B virus strains
Putting virtual rehab for stroke patients to the test
3 "Strong Buy" Healthcare Stocks Under $5 With Triple-Digit Growth Prospects
The second wave is here. Have you installed the COVID Alert app?
Coronavirus: why I support the world's first COVID vaccine challenge trial
Life in phase III: How effective data management can support NHS Trusts to hit their targets
Statins reduce COVID-19 severity, likely by removing cholesterol that virus uses to infect
UofA lab uncovers new mechanism of action against SARS-CoV-2 by antiviral drug remdesivir
FDA’s New Moves Can’t Allay Coronavirus Vaccine Fears
Fujifilm’s Avigan shown to be effective in Japanese Phase 3 trial for Covid-19
Fujifilm’s Avigan shown to be effective in Japanese Phase-3 trial for Covid-19
3 "Strong Buy" Stocks That Are Flirting With a Bottom
RedHill Gets Brazil’s Nod For Covid-19 Study With Opaganib
FDA’s review date for BMS’ ide-cel sneaks under the CVR wire
COVID-19: Does Sweden Have Herd Immunity?
Mount Sinai researchers develop COVID-19 mortality prediction model
University of Cincinnati researchers to study the effects of razuprotafib on COVID-19 patients
How and when will we know that a COVID-19 vaccine is safe and effective?
3 research-based ways to cope with the uncertainties of pandemic life
Companies turn to convertibles for much-needed cash
Experts Worry As Leading COVID-19 Vaccines Adopt Trial Shortcuts In "Rush For Results"
Henry Ford study demonstrates UV-C light is effective for killing COVID-19 on N95s
Exercise hormone may modulate genes associated with replication of novel coronavirus
Operation Warp Speed: Are Bad Vaccine Trial Outcomes Good?
Goldman Sachs: These 3 Stocks Are Poised to Surge by at Least 50%